Prof Tanya Wildes speaks to ecancer at the SIOG 2019 meeting in Geneva about how polypharmacy affects mobility in older patients.
Firstly, Prof Wildes explored some of the current mobility tests and their conclusions in geriatric oncology assessments.
She then looked at how some of the conclusions (e.g. an increase in falls) also were the same risks associated of certain medications, and that this may impact mobility.
Prof Wildes concluded that there needs to be an accurate representation of the patient's medication so that mobility can be reviewed and understood in the context of their polypharmacy regimen.
More information on the Cancer and Ageing Research Group mentioned in the video can be found here.
This service has been kindly supported by unrestricted grants from Janssen Oncology and Sanofi Genzyme.